China
· Delayed Price · Currency is CNY Jilin Aodong Pharmaceutical Group Statistics
Total Valuation
Jilin Aodong Pharmaceutical Group has a market cap or net worth of CNY 19.82 billion. The enterprise value is 18.98 billion.
| Market Cap | 19.82B |
| Enterprise Value | 18.98B |
Important Dates
The next estimated earnings date is Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | Jul 9, 2024 |
Share Statistics
Jilin Aodong Pharmaceutical Group has 1.20 billion shares outstanding. The number of shares has decreased by -11.08% in one year.
| Shares Outstanding | 1.20B |
| Shares Change (YoY) | -11.08% |
| Shares Change (QoQ) | +6.28% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 7.79% |
| Float | 820.72M |
Valuation Ratios
The trailing PE ratio is 20.37 and the forward PE ratio is 8.54.
| PE Ratio | 20.37 |
| Forward PE | 8.54 |
| PS Ratio | 5.77 |
| PB Ratio | 0.70 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 93.96, with an EV/FCF ratio of -118.36.
| EV / Earnings | 20.32 |
| EV / Sales | 5.79 |
| EV / EBITDA | 93.96 |
| EV / EBIT | n/a |
| EV / FCF | -118.36 |
Financial Position
The company has a current ratio of 1.74, with a Debt / Equity ratio of 0.08.
| Current Ratio | 1.74 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 10.67 |
| Debt / FCF | -13.45 |
| Interest Coverage | -0.25 |
Financial Efficiency
Return on equity (ROE) is 3.25% and return on invested capital (ROIC) is -0.07%.
| Return on Equity (ROE) | 3.25% |
| Return on Assets (ROA) | -0.06% |
| Return on Capital (ROIC) | -0.07% |
| Revenue Per Employee | 580,561 |
| Profits Per Employee | 165,455 |
| Employee Count | 5,646 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 1.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.13% in the last 52 weeks. The beta is 0.53, so Jilin Aodong Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +4.13% |
| 50-Day Moving Average | 13.66 |
| 200-Day Moving Average | 14.29 |
| Relative Strength Index (RSI) | 64.25 |
| Average Volume (20 Days) | 28,201,244 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jilin Aodong Pharmaceutical Group had revenue of CNY 3.28 billion and earned 934.16 million in profits. Earnings per share was 0.81.
| Revenue | 3.28B |
| Gross Profit | 1.42B |
| Operating Income | -33.87M |
| Pretax Income | 853.71M |
| Net Income | 934.16M |
| EBITDA | 174.30M |
| EBIT | -33.87M |
| Earnings Per Share (EPS) | 0.81 |
Balance Sheet
The company has 3.26 billion in cash and 2.16 billion in debt, giving a net cash position of 1.10 billion or 0.92 per share.
| Cash & Cash Equivalents | 3.26B |
| Total Debt | 2.16B |
| Net Cash | 1.10B |
| Net Cash Per Share | 0.92 |
| Equity (Book Value) | 28.62B |
| Book Value Per Share | 23.71 |
| Working Capital | 2.60B |
Cash Flow
In the last 12 months, operating cash flow was 333.42 million and capital expenditures -493.79 million, giving a free cash flow of -160.37 million.
| Operating Cash Flow | 333.42M |
| Capital Expenditures | -493.79M |
| Free Cash Flow | -160.37M |
| FCF Per Share | -0.13 |
Margins
Gross margin is 43.40%, with operating and profit margins of -1.03% and 28.50%.
| Gross Margin | 43.40% |
| Operating Margin | -1.03% |
| Pretax Margin | 26.04% |
| Profit Margin | 28.50% |
| EBITDA Margin | 5.32% |
| EBIT Margin | -1.03% |
| FCF Margin | -4.89% |
Dividends & Yields
This stock pays an annual dividend of 0.40, which amounts to a dividend yield of 2.34%.
| Dividend Per Share | 0.40 |
| Dividend Yield | 2.34% |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 46.85% |
| Buyback Yield | 11.08% |
| Shareholder Yield | 13.42% |
| Earnings Yield | 4.91% |
| FCF Yield | -0.81% |
Stock Splits
The last stock split was on June 19, 2017. It was a forward split with a ratio of 1.3.
| Last Split Date | Jun 19, 2017 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
Jilin Aodong Pharmaceutical Group has an Altman Z-Score of 3.32.
| Altman Z-Score | 3.32 |
| Piotroski F-Score | n/a |